[go: up one dir, main page]

ZA200605657B - Derivatives of N-'(1,5-diphenyl-1H-pyrazol-3-yl) sulphonamide with CB1 receptor affinity - Google Patents

Derivatives of N-'(1,5-diphenyl-1H-pyrazol-3-yl) sulphonamide with CB1 receptor affinity

Info

Publication number
ZA200605657B
ZA200605657B ZA200605657A ZA200605657A ZA200605657B ZA 200605657 B ZA200605657 B ZA 200605657B ZA 200605657 A ZA200605657 A ZA 200605657A ZA 200605657 A ZA200605657 A ZA 200605657A ZA 200605657 B ZA200605657 B ZA 200605657B
Authority
ZA
South Africa
Prior art keywords
sulphonamide
pyrazol
diphenyl
derivatives
receptor affinity
Prior art date
Application number
ZA200605657A
Other languages
English (en)
Inventor
Francis Barth
Christian Congy
Serge Martinez
Murielle Rinaldi-Carmona
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ZA200605657B publication Critical patent/ZA200605657B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
ZA200605657A 2004-01-12 2005-01-07 Derivatives of N-'(1,5-diphenyl-1H-pyrazol-3-yl) sulphonamide with CB1 receptor affinity ZA200605657B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0400257A FR2864958B1 (fr) 2004-01-12 2004-01-12 Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.

Publications (1)

Publication Number Publication Date
ZA200605657B true ZA200605657B (en) 2007-12-27

Family

ID=34684951

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200605657A ZA200605657B (en) 2004-01-12 2005-01-07 Derivatives of N-'(1,5-diphenyl-1H-pyrazol-3-yl) sulphonamide with CB1 receptor affinity

Country Status (31)

Country Link
US (1) US7294645B2 (xx)
EP (1) EP1720837B1 (xx)
JP (1) JP4723514B2 (xx)
KR (1) KR20060105050A (xx)
CN (1) CN1910157A (xx)
AR (1) AR047096A1 (xx)
AT (1) ATE465995T1 (xx)
AU (1) AU2005209441B2 (xx)
CA (1) CA2551141C (xx)
CR (1) CR8468A (xx)
CY (1) CY1110651T1 (xx)
DE (1) DE602005020907D1 (xx)
DK (1) DK1720837T3 (xx)
EC (1) ECSP066695A (xx)
ES (1) ES2344850T3 (xx)
FR (1) FR2864958B1 (xx)
HR (1) HRP20100283T8 (xx)
IL (1) IL176710A0 (xx)
MA (1) MA28422B1 (xx)
NO (1) NO20063621L (xx)
NZ (1) NZ548442A (xx)
PL (1) PL1720837T3 (xx)
PT (1) PT1720837E (xx)
RS (1) RS51365B (xx)
RU (1) RU2366657C2 (xx)
SI (1) SI1720837T1 (xx)
TN (1) TNSN06203A1 (xx)
TW (1) TWI323255B (xx)
UA (1) UA85079C2 (xx)
WO (1) WO2005073197A1 (xx)
ZA (1) ZA200605657B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
FR2880023B1 (fr) * 2004-12-23 2007-02-23 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
FR2880890B1 (fr) * 2005-01-19 2007-03-30 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide, leur preparation et leur application en therapeutique
FR2881744B1 (fr) 2005-02-09 2007-04-27 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
FR2894578B1 (fr) * 2005-12-12 2008-02-01 Sanofi Aventis Sa Derives heterocycliques, leur preparation et leur application en therapeutique.
FR2894579B1 (fr) * 2005-12-12 2008-01-18 Sanofi Aventis Sa Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
EP1829867A1 (en) * 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Imidazole compounds having pharmaceutical activity towards the sigma receptor
FR2899899A1 (fr) * 2006-04-14 2007-10-19 Sanofi Aventis Sa Derives d'aminomethyl pyridine, leur preparation et leur application en therapeutique
DE602006014532D1 (de) * 2006-07-11 2010-07-08 Sanofi Aventis N-Ä(1,5-diphenyl-1H-pyrazol-3-yl)methylÜsulfonamid-Derivate Antagonisten der CB1 Rezeptoren der Cannabinoide
JP2008019205A (ja) * 2006-07-12 2008-01-31 Sanofi-Aventis Ｎ−［（１，５−ジフェニル−１ｈ−ピラゾール−３−イル）メチル］スルホンアミド誘導体、その調製法および治療におけるその応用
US7297710B1 (en) * 2006-07-12 2007-11-20 Sanofi-Aventis Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
WO2008062424A2 (en) * 2006-07-31 2008-05-29 Cadila Healthcare Limited Substituted 4,5-dihydro-1h-pyrazole derivatives as cannabinoid modulators
US7875647B2 (en) 2006-09-29 2011-01-25 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
EP1911747A1 (en) * 2006-10-11 2008-04-16 Laboratorios del Dr. Esteve S.A. Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators
FR2911136B1 (fr) * 2007-01-05 2009-02-20 Sanofi Aventis Sa Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
FR2919184A1 (fr) * 2007-07-26 2009-01-30 Sanofi Aventis Sa L'acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament.
EP2885304B8 (en) 2012-08-16 2016-12-07 Janssen Pharmaceutica NV Pyrrolopyrazoles as n-type calcium channel blockers
EP2885278B1 (en) 2012-08-16 2016-08-03 Janssen Pharmaceutica N.V. Substituted pyrazoles as n-type calcium channel blockers
WO2014111356A1 (en) * 2013-01-17 2014-07-24 F. Hoffmann-La Roche Ag Oxytocin receptor agonists for the treatment of cns diseases
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
KR101685993B1 (ko) * 2014-05-15 2016-12-13 한국과학기술연구원 전압개폐 칼슘이온채널 억제 활성화능을 갖는 ｎ-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물
AU2017260706B2 (en) 2016-05-04 2023-05-11 Inmed Pharmaceuticals Inc. Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
WO2019056123A1 (en) 2017-09-22 2019-03-28 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN
WO2022109292A1 (en) * 2020-11-20 2022-05-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for inhibiting cb1 activity
WO2025090133A1 (en) 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Compositions and methods for use of cannabinol compounds in neuroprotection
WO2025090587A1 (en) 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Cannabinoids compounds and their use in the treatment of neuronal disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
RU2165542C2 (ru) * 1999-04-27 2001-04-20 Открытое акционерное общество "АВТОВАЗ" Модульный агрегат топливоподачи системы питания двигателя транспортного средства

Also Published As

Publication number Publication date
US7294645B2 (en) 2007-11-13
FR2864958B1 (fr) 2006-02-24
DK1720837T3 (da) 2010-08-23
CY1110651T1 (el) 2015-06-10
RS51365B (sr) 2011-02-28
DE602005020907D1 (de) 2010-06-10
ECSP066695A (es) 2006-10-31
JP4723514B2 (ja) 2011-07-13
AU2005209441A1 (en) 2005-08-11
HRP20100283T8 (hr) 2010-10-31
JP2007517839A (ja) 2007-07-05
TWI323255B (en) 2010-04-11
NZ548442A (en) 2009-10-30
EP1720837A1 (fr) 2006-11-15
ATE465995T1 (de) 2010-05-15
IL176710A0 (en) 2006-10-31
CR8468A (es) 2007-03-06
AU2005209441B2 (en) 2010-12-23
PL1720837T3 (pl) 2010-09-30
TNSN06203A1 (en) 2007-11-15
EP1720837B1 (fr) 2010-04-28
SI1720837T1 (sl) 2010-08-31
NO20063621L (no) 2006-10-10
FR2864958A1 (fr) 2005-07-15
TW200535135A (en) 2005-11-01
HRP20100283T1 (hr) 2010-08-31
ES2344850T3 (es) 2010-09-08
PT1720837E (pt) 2010-05-14
KR20060105050A (ko) 2006-10-09
MA28422B1 (fr) 2007-02-01
RU2006129297A (ru) 2008-02-20
AR047096A1 (es) 2006-01-04
CA2551141A1 (fr) 2005-08-11
WO2005073197A1 (fr) 2005-08-11
UA85079C2 (xx) 2008-12-25
CA2551141C (fr) 2011-06-07
US20070021486A1 (en) 2007-01-25
RU2366657C2 (ru) 2009-09-10
CN1910157A (zh) 2007-02-07

Similar Documents

Publication Publication Date Title
ZA200605657B (en) Derivatives of N-'(1,5-diphenyl-1H-pyrazol-3-yl) sulphonamide with CB1 receptor affinity
IL158997A0 (en) New indole derivatives with 5-ht6 receptor affinity
IL177218A0 (en) 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
DK1429761T3 (da) Hidtil ukendte 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning
NO20032892L (no) 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning
PL376479A1 (en) 4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity
DK1720836T3 (da) 6-substituerede 2,3,4,5-tetrahydro-1h-benzo [d]azepiner som 5-ht2c-receptoragonister
DE60218340D1 (de) 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
EP1863810A4 (en) NEW TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLDERIVATE AS CB1 'RECEPTOR LIGANDS
ATE406361T1 (de) 3-substituierte 5,6-diaryl-pyrazin-2- carbonsäureamid- und -2-sulfonsäureamidderivative als cb1 modulatoren
AU2003243637A1 (en) Cannabinoid receptor agonists
EP1814550A4 (en) ANTAGONISTS OF N-SULFONYLPIPERIDINE CANNABINOID RECEPTOR 1
AU2003244480A1 (en) Sulphonyl compounds with 5 -ht6 receptor affinity
IL185035A0 (en) Derivatives of n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine
IL198523A0 (en) Substituted 2,5-dfflydro-3h-pyrazolo[4,3-c]pyridazin-3-one derivatives, preparation thereof and use of same as cannabinoid cb1 receptor ligands
IL189390A0 (en) (indol-3-yl)heterocycle derivatives as agonists of the cannabinoid cb1 receptor
SI1725232T1 (sl) (Indol-3-il)-heterociklični derivati kot agonisti kanabinoidnega CB1 receptorja
GB2406598B (en) Foldable gooseneck
IL177571A0 (en) (indol-3-yl) heterocycle derivatives as agonists of the cannabinoid cb1 receptor
ATE500228T1 (de) 4,5-dihydro-(1h)-pyrazol-derivate als cannabinoid-cb1-rezeptormodulatoren
ZA200606563B (en) 3-Substituted 1,5-diphenylpyrazole derivatives useful as CB1 Modulators
AU2003206931A1 (en) Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors
ZA200607095B (en) (Indol-3-yl)-heterocycle derivatives as agonists of the cannabinoid CB1 receptor
DK1373216T3 (da) 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk aktivitet
HK1109623A (en) 1,2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands